IRIS
Contact Us

Hydrazine/Hydrazine sulfate

CASRN 302-01-2 | DTXSID3020702

On this page:

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (14 pp, 119 K) Last Updated:

Not assessed under the IRIS Program.

Reference Concentration for Inhalation Exposure (RfC) (PDF) (14 pp, 119 K)

Not assessed under the IRIS Program.

Cancer Assessment

Weight of Evidence for Cancer (PDF) (14 pp, 119 K) Last Updated: 09/07/1988

WOE Characterization Framework for WOE Characterization
B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986)
Basis:
  • Tumors have been induced in mice, rats and hamsters following oral, inhalation or intraperitoneal administration of hydrazine and sulfate. Hydrazine is mutagenic in numerous assays.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (14 pp, 119 K)

Oral Slope Factor: 3.0 per mg/kg-day
Drinking Water Unit Risk: 8.5 x 10-5 per µg/L
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Hepatic
Tumor type(s): Hepatoma (Biancifiori, 1970)

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (14 pp, 119 K)

Inhalation Unit Risk: 4.9 x 10-3 per µg/m3
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Respiratory
Tumor type(s): Nasal cavity adenoma or adenocarcinoma (MacEwen et al., 1981)

Other EPA Information

Additional EPA toxicity information may be available by visiting the following sites:

Related Links

Tumor Sites

Hepatic
Hepatic

Respiratory
Respiratory

Chemical Structure

Hydrazine/Hydrazine sulfate

Synonyms

  • Hydrazine
  • Hydrazine, anhydrous
  • Hydrazine/hydrazine sulfate
  • 302-01-2
Contact Us to ask a question, provide feedback, or report a problem.